Share: LUNG CANCER NEWS AND INFORMATION
|
News and Information
EML4-ALK Mutation: A critical link to the causes of lung cancer in never and current non-smokers. If you fall into this category, demand that your doctors test your tumors for a genetic mutation that may be at the root cause of your cancer and also render you resistant to conventional chemotherapy. Recent advances in treatment that involve nano-medicine and immunotherapy are being shown to be highly effective in treating lung cancer caused by identifiable genetic mutations such as EGFR, K-RAS, EML4-ALK and most other known mutations. Beth Israel Medical Center and the Dana Farber Cancer Institute, both in Boston, MA are at the forefront of these breakthroughs. Take control of your lung cancer treatment and contact them. It may save your life!
Lung cancer kills more people every year than prostate, breast and colon cancer combined. The social stigma of smoking lingers in public perception, but the face of lung cancer isn’t the face you think it is. More and more it is the face of a 20, 30 or 40 year old. Increasingly, it is the face of one who never smoked; of those who haven’t, it is twice as likely to be the face of a woman. In the same 30 years, consider the drastically different outcomes in 2009 based on vastly different national responses to breast and lung cancer: Source: http://seer.cancer.gov/statfacts/html/breast.html
|
Breast Cancer:
192,400 diagnosed/40,000 deaths
5 year survival: 89%
Per capita $: $14,000
| Lung Cancer:
220,000 diagnosed/160,000 deaths
15.6%
$1,300 SHAMEFUL AND OUTRAGEOUS!!!
|
Lung cancer doesn’t usually make headlines unless it effects a celebrity, so it’s likely you missed perhaps the biggest breakthrough on the road to early diagnosis and treatment in 30 years! Go to EMPOWER to see what you can do to have an impact RIGHT NOW.
|
University of Cincinnati (UC) cancer cell biologists have identified a distinct gene linked to increased lung cancer susceptibility and development. They say this gene-known as RGS17- could result in a genetic predisposition to develop lung cancer for people with a strong family history of the disease. With further investigation, they believe the gene could be used to identify high-risk patients who may benefit from earlier, more aggressive lung cancer screening. Marshall Anderson, PhD, and his colleagues report their findings in the April 15, 2009, issue of the journal Clinical Cancer Research: “Understanding how the RGS17 gene impacts cancer development could change clinical diagnosis and treatment as radically as discovery of the breast cancer genes (BRCA1 and BRCA2) did," explains Anderson, who has led the multi-institutional Genetic Epidemiology of Lung Cancer Consortium (GELCC) studying the genetic basis of lung cancer since 1997. "A proven genetic test could help us identify people at risk before the disease progresses" including people with known risk factors, family history, or heredity, occurring in multiple members of the same family. In 2004, Anderson's team reported the first genetic evidence of a major lung cancer "susceptibility locus" on chromosome 6, and evidence of a susceptibility region on three other chromosomes.
Source: www.uc.edu
|
|